Search results
Showing 3151 to 3200 of 4090 results for patient
This guideline covers long-acting reversible contraception. It aims to increase the use of long-action reversible contraception by improving the information given to women about their contraceptive choices.
Cytosponge for detecting abnormal cells in the oesophagus (MIB240)
NICE has developed a medtech innovation briefing (MIB) on Cytosponge for detecting abnormal cells in the oesophagus .
For which people with impetigo are antiseptics as effective as antibiotics?
decision, taking local antimicrobial resistance data into account alongside patient preference, practicalities of administration,...
Ublituximab for treating relapsing multiple sclerosis (TA1025)
Evidence-based recommendations on ublituximab (Briumvi) for treating relapsing multiple sclerosis in adults.
Acoramidis for treating transthyretin amyloidosis with cardiomyopathy (TA1121)
Evidence-based recommendations on acoramidis (Beyonttra) for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]
Awaiting development Reference number: GID-TA11307 Expected publication date: 06 January 2027
Awaiting development Reference number: GID-TA11773 Expected publication date: 27 May 2027
Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]
In development Reference number: GID-TA11445 Expected publication date: TBC
Therapeutic amnioinfusion for oligohydramnios during pregnancy (excluding labour) (HTG124)
Evidence-based recommendations on therapeutic amnioinfusion for treating oligohydramnios during pregnancy (excluding labour). This involves injecting a substance similar to amniotic fluid into the space around the baby.
View recommendations for HTG124Show all sections
Sections for HTG124
Evidence-based recommendations on corneal endothelial transplantation. This involves replacing only the innermost layers of the cornea with a healthy section from a donor eye without disturbing the overall structure.
View recommendations for HTG195Show all sections
Sections for HTG195
The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)
NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system
This guidance has been updated and replaced by NICE guideline CG172.
Awaiting development Reference number: GID-TA11437 Expected publication date: TBC
Awaiting development Reference number: GID-TA11637 Expected publication date: TBC
In development Reference number: GID-TA11635 Expected publication date: 26 August 2026
In development Reference number: GID-IPG10441 Expected publication date: 17 December 2026
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence in mammography .
Sexually transmitted infections: condom distribution schemes (NG68)
This guideline covers condom distribution schemes. The aim is to reduce the risk of sexually transmitted infections (STIs). In addition, these schemes can provide a good introduction to broader sexual and reproductive health services, especially for younger people, and help prevent unplanned pregnancies.
We're working with colleagues to ensure that virtual wards are used in a way that maximises the value for patients and the NHS.
Novii Wireless Patch System for maternal and fetal monitoring (MIB228)
NICE has developed a medtech innovation briefing (MIB) on Novii Wireless Patch System for maternal and fetal monitoring .
Evidence-based recommendations on faricimab (Vabysmo) for treating visual impairment caused by macular oedema after retinal vein occlusion in adults.
Evidence-based recommendations on rucaparib (Rubraca) for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely or partially responded to platinum-based chemotherapy in adults.
Risankizumab for treating moderately to severely active ulcerative colitis (TA998)
Evidence-based recommendations on risankizumab (Skyrizi) for treating moderately to severely active ulcerative colitis in adults.
Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.
Evidence-based recommendations on betula verrucosa (Itulazax 12 SQ Bet) for treating moderate to severe allergic rhinitis or conjunctivitis caused by pollen from trees in the birch allergy group in adults.
Show all sections
Facial erythema of rosacea: brimonidine tartrate gel (ESNM43)
Summary of the evidence on brimonidine tartrate gel for treating facial erythema of rosacea to inform local NHS planning and decision-making
In development Reference number: GID-IPG10405 Expected publication date: 19 November 2026
Artificial intelligence (AI) technologies to help detect prostate cancer on MRI
In development Reference number: GID-HTE10089 Expected publication date: 12 November 2026
Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac death
In development Reference number: GID-IPG10437 Expected publication date: TBC
Gambling-related harms: identification, assessment and management (NG248)
This guideline covers identifying, assessing and treating gambling-related harms. This includes people aged 18 and over who are experiencing gambling that harms, and people of any age affected by someone close to them who is experiencing gambling that harms.
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical modalities, and the impact of acne vulgaris on mental health and wellbeing.
Electrosurgery (diathermy and coblation) for tonsillectomy (HTG96)
Evidence-based recommendations on electrosurgery (diathermy and coblation) for tonsillectomy. This involves using heat (diathermy) to 'cut' away the tonsils or radiofrequency energy (coblation) to cut through the soft tissue attaching the tonsils.
View recommendations for HTG96Show all sections
This quality standard covers managing faecal (bowel) incontinence in adults (aged 18 and over) in the community (at home and in care homes) and in all hospital departments. It includes assessment of bowel control problems, advice and support, and treatment options. It describes high-quality care in priority areas for improvement.
View quality statements for QS54Show all sections
Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication.
Bipolar, schizophrenia and other psychoses: register (lithium therapy) (IND256)
This indicator covers the contractor establishing and maintaining a register of patients with schizophrenia, bipolar affective disorder and other psychoses, and other patients on lithium therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM240
This indicator covers establishing and maintaining a register of all patients aged 17 or over with diabetes mellitus, which specifies the type of diabetes where a diagnosis has been confirmed. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM41
Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]
Awaiting development Reference number: GID-TA11530 Expected publication date: TBC
In development Reference number: GID-TA11636 Expected publication date: 26 August 2026
showing that having patiromer improved length or quality of life or allowed patients to stay on optimal doses of...
This indicator covers the proportion of people who have had an acute stroke who receive thrombolysis for stroke. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG50
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)
Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.
Evidence-based recommendations on low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. This involves applying low-energy lasers to the affected tissue.
View recommendations for HTG472Show all sections
Before 2022, we used different processes for assessing technologies. You can view the previous process and methods guides below.
Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)
Evidence-based recommendations on mirikizumab (Omvoh) for treating moderately to severely active ulcerative colitis in adults.
This indicator covers the percentage of patients (excluding those on the CKD register) prescribed long-term (chronic) oral non-steroidal anti-inflammatory drugs (NSAIDs) who have had an eGFR measurement in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM214.
This indicator covers the proportion of patients with ST-segment elevation myocardial infarction (STEMI) who had coronary reperfusion therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG91
This indicator covers producing a register of all patients aged 16 years and over with rheumatoid arthritis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM55
In development Reference number: GID-HTE10069 Expected publication date: TBC
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]
In development Reference number: GID-TA11025 Expected publication date: 10 February 2027